Benjamin Edwards Inc. Buys 57,948 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Benjamin Edwards Inc. lifted its stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 18,454.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 58,262 shares of the company's stock after purchasing an additional 57,948 shares during the period. Benjamin Edwards Inc.'s holdings in 10x Genomics were worth $1,315,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of TXG. Allspring Global Investments Holdings LLC grew its stake in 10x Genomics by 134.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,637 shares of the company's stock worth $32,000 after purchasing an additional 939 shares during the period. GAMMA Investing LLC grew its position in shares of 10x Genomics by 451.8% in the 3rd quarter. GAMMA Investing LLC now owns 1,545 shares of the company's stock worth $35,000 after buying an additional 1,265 shares during the period. Capital Performance Advisors LLP bought a new position in shares of 10x Genomics in the 3rd quarter worth about $35,000. First Horizon Advisors Inc. lifted its position in 10x Genomics by 74.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 1,898 shares of the company's stock valued at $37,000 after acquiring an additional 808 shares during the period. Finally, Blue Trust Inc. boosted its stake in 10x Genomics by 136.5% during the third quarter. Blue Trust Inc. now owns 1,776 shares of the company's stock worth $40,000 after acquiring an additional 1,025 shares in the last quarter. Institutional investors own 84.68% of the company's stock.

10x Genomics Stock Up 4.2 %

TXG traded up $0.64 during midday trading on Friday, reaching $15.87. The company had a trading volume of 1,301,314 shares, compared to its average volume of 1,741,731. 10x Genomics, Inc. has a 1 year low of $12.95 and a 1 year high of $57.90. The company has a market cap of $1.92 billion, a P/E ratio of -9.95 and a beta of 1.84. The business has a 50-day moving average of $16.38 and a two-hundred day moving average of $19.32.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.04. The business had revenue of $151.65 million for the quarter, compared to the consensus estimate of $158.84 million. 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. The company's revenue for the quarter was down 1.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.51) earnings per share. On average, equities research analysts predict that 10x Genomics, Inc. will post -1.4 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on TXG shares. The Goldman Sachs Group lowered their target price on shares of 10x Genomics from $16.00 to $14.00 and set a "sell" rating for the company in a report on Wednesday, October 30th. Leerink Partnrs raised 10x Genomics to a "strong-buy" rating in a report on Tuesday, September 3rd. JPMorgan Chase & Co. reduced their price target on 10x Genomics from $20.00 to $14.00 and set a "neutral" rating for the company in a report on Wednesday, October 30th. UBS Group dropped their price target on shares of 10x Genomics from $25.00 to $20.00 and set a "neutral" rating on the stock in a research note on Wednesday, October 30th. Finally, Morgan Stanley reduced their price objective on shares of 10x Genomics from $50.00 to $46.00 and set an "overweight" rating for the company in a research note on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, 10x Genomics presently has a consensus rating of "Moderate Buy" and a consensus price target of $29.19.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.